Registration Options

Activity Dates: 01/23/2015 - 01/23/2016

This course is closed. Please look for other available products in AAPP Education+Resources.

Target Audience

If you are a pharmacist, nurse practitioner or other healthcare professional, we invite you to participate in this online course.

Activity Overview

Major depressive disorder (MDD) is becoming one of the most prevalent and proliferating public health concerns worldwide because of its high rate of morbidity, recurrence, and associated suicide, all of which result in a profound burden to both the individual and society. Clinical pharmacists face the everyday challenge of providing individualized, safe, and effective care for patients with MDD. Through two interactive modules, this activity will review recent clinical data and guidelines in the management of MDD. Case studies will introduce potential treatment strategies, communication tools, and other data for learners to consider.

  • Module 1 will cover “The Pathogenesis of Depression: From Traditional Theories to Novel Concepts”
  • Module 2 will cover “Treatment Selection in Depression: The Role of Pharmacists in Optimizing Therapeutic Outcomes”

This educational activity is jointly sponsored by the College of Psychiatric and Neurologic Pharmacists and Spire Learning.

Faculty Information and Disclosures

Patrick R. Finley, PharmD, BCPP
Matthew A. Fuller, PharmD, BCPS, BCPP, FASHP
Roger W. Sommi, PharmD, FCCP, BCPP
Amy Werremeyer, PharmD, BCPP

View biographical information and disclosures

Learning Objectives

Module 1

  1. Examine the monoamine hypotheses of depression
  2. Apply current theories on the role of serotonin and its varying receptor profiles to an understanding of the dysregulation of mood, cognition, and behavior
  3. Utilize an understanding of the neurobiology of depression to examine clinical updates on current and novel treatment paradigms in depression
  4. Interpret recent clinical trial data implicating the concomitant modulation of several serotonergic receptor systems in optimizing therapeutic outcomes in MDD

Module 2

  1. Modify treatment plans for MDD by taking into account the benefits/limitations of traditional antidepressants in achieving symptomatic remission and recovery
  2. Demonstrate the evidence-based need for emerging therapies with novel mechanisms of action in targeting residual symptoms in depression management
  3. Apply an understanding of the importance of symptomatic remission and recovery in achieving optimal outcomes in depression management
  4. Illustrate the limitations of current health system management of depression and the evolving role of the clinical pharmacist in optimizing outcomes

Continuing Education Credit and Disclosures

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Each module will provide 1.0 contact hours (0.1 CEUs), for a total of 2 contact hours (0.2 CEUs) of application-based continuing education credit. The ACPE universal program numbers assigned to this course are 0284-9999-15-076-H01-P and 0284-9999-15-077-H01-P (2.0 contact hours).

Grant Support

This activity is supported by an educational grant from Takeda Pharmaceuticals International, Inc., U.S. Region, and Lundbeck.